Crinetics Pharmaceuticals, Inc. will host a conference call and webcast on January 5, 2026, at 8:30 a.m. ET to discuss PALSONIFY™ commercialization and Phase 2 trial results of atumelnant for congenital adrenal hyperplasia. Management will provide updates and a live Q&A session. The company focuses on developing therapies for endocrine diseases and tumors, with PALSONIFY™ approved for acromegaly in adults. Their pipeline includes atumelnant for congenital adrenal hyperplasia and CRN09682 for neuroendocrine tumors. Investors and media can contact Gayathri Diwakar and Natalie Badillo, respectively, for more information.

Read more at GlobeNewswire: Crinetics Pharmaceuticals to Provide PALSONIFY Business